Archive \ Volume.12 2021 Issue 1

Does CD31 possess a role in patients with type 2 diabetes mellitus? a preliminary study

Mohamed Mohey , Hanan Soliman , AhmedOkasha
Abstract

Diabetes mellitus (DM) is a common endocrinopathy seen in the general population. It is one of the fundamental wellbeing fears in developing countries and is a serious metabolic disorder that causes considerable disease and mortality with micro- and macro-vascular complications. Long-lasting diabetes is poorly controlled and often leads to nephropathy and cardiovascular complications. To a greater extent, studies indicate that T2D.M is a protracted inflammatory disease associated with the immune system. The present study was therefore aimed to investigate immune changes by evaluating the CD31 marker. Subjects were divided into two groups: healthy people (control group) and diabetic patients of type 2 (diabetic group). Our results showed a significant increase in CD31in the diabetic group, in comparison with the control group. Also, WBC and lymphocyte count significantly increased in the diabetic group in comparison with the control group. To sum up, the evaluation of CD31 showed a noteworthy increment in HbA1c of diabetics compared to the control group.



How to cite:
Mohey M, Soliman H, AhmedOkasha. Does CD31 possess a role in patients with type 2 diabetes mellitus? a preliminary study. Arch Pharma Pract 2021;12(1):1-6

Download Citation